Sort
10,766 grants matching “checkpoint inhibitor”
Regulation of translation through the human translation initiation factor eIF5B
$155,736Assen G Marintchev · Boston University Medical Campus · K01 · FY2009 · CA
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
$155,680Robert H Blelloch · University Of California, San Francisco · U01 · FY2021 · CA
: Regulation of the cancer stem cell phenotype in salivary gland cancers
$155,500Stephen B. Keysar · University Of Colorado Denver · R03 · FY2019 · DE
Deregulation of the Ubiquitin/26S Proteasome Pathway in AT cells: Role of ISG15
$155,313Shyamal D Desai · Lsu Health Sciences Center · R21 · FY2008 · NS
Remodeling host immunity in oral cancer with personalized RNA nanoparticle vaccines
$155,304Natalie Lea Silver · Cleveland Clinic Lerner Com-Cwru · K08 · FY2023 · DE
Remodeling host immunity in oral cancer with personalized RNA nanoparticle vaccines
$155,304Natalie Lea Silver · University Of Florida · K08 · FY2020 · DE
Remodeling host immunity in oral cancer with personalized RNA nanoparticle vaccines
$155,304Natalie Lea Silver · Cleveland Clinic Lerner Com-Cwru · K08 · FY2022 · DE
Remodeling host immunity in oral cancer with personalized RNA nanoparticle vaccines
$155,304Natalie Lea Silver · Cleveland Clinic Lerner Com-Cwru · K08 · FY2024 · DE
Characterization of an inflammasome-unleashing approach to improve anti-PD-1 therapy in cancer
$155,024Marcelo Hill · Ardan Pharma S A S · R21 · FY2021 · CA
P30 Administrative Supplement for Early-Onset Cancer Research: Repurposing orphan drugs for early-onset endometrial cancer
$154,000Boris Pasche · Wayne State University · P30 · FY2025 · CA
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
$153,850Bolni Marius Nagalo · Mayo Clinic Arizona · K01 · FY2018 · CA
Tunneling Nanotube Inhibitors for Cancer Immunotherapy
$153,677Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2024 · CA
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy
$153,500Yong Qin · University Of Texas El Paso · R16 · FY2023 · GM
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy
$153,500Yong Qin · University Of Texas El Paso · R16 · FY2025 · GM
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy
$153,500Yong Qin · University Of Texas El Paso · R16 · FY2024 · GM
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy
$153,500Yong Qin · University Of Texas El Paso · R16 · FY2022 · GM
Translation and validation of non-invasive measurement of PD-L1 levels with positron emission tomography (PET) in head and neck malignancies and intracranial metastases
$153,480Julius Chapiro · Yale University · R21 · FY2023 · CA
Dissecting histone regulation of the DNA-damage checkpoint in proliferating cells
$153,399Amanda A Amodeo · Dartmouth College · P20 · FY2023 · GM
The role of AHR in modulatingimmunotherapy response and adverse events in bladder cancer
$153,160Hyo Sik Jang · Van Andel Research Institute · K99 · FY2025 · CA
The role of AHR in modulatingimmunotherapy response and adverse events in bladder cancer
$153,160Hyo Sik Jang · Van Andel Research Institute · K99 · FY2024 · CA
DNA Damage and Immunogenicity in Ewing Sarcoma
$152,995Kelly Bailey · University Of Pittsburgh At Pittsburgh · K08 · FY2022 · CA
DNA Damage and Immunogenicity in Ewing Sarcoma
$152,995Kelly Bailey · University Of Pittsburgh At Pittsburgh · K08 · FY2023 · CA
DNA Damage and Immunogenicity in Ewing Sarcoma
$152,995Kelly Bailey · University Of Pittsburgh At Pittsburgh · K08 · FY2024 · CA
DNA Damage and Immunogenicity in Ewing Sarcoma
$152,995Kelly Bailey · University Of Pittsburgh At Pittsburgh · K08 · FY2021 · CA
Proj 4 - Enhancing the Potency and Durability of Immunotherapies
$152,924Crystal L Mackall · Children'S Hosp Of Philadelphia · P01 · FY2020 · CA